Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Biogen Idec Inc. (BIIB): A Strong Growth Opportunity In Multiple Sclerosis

Page 1 of 2

Biogen Idec Inc.(NASDAQ:BIIB) has just moved to reinforce its dominance in the multiple sclerosis treatment market by striking a deal to buy the 50% rights to Tysabri that it does not own from its partner Elan. Biogen’s MS drugs account for about 30% of the roughly $12 billion global MS market, and Tysabri is regarded as the most effective treatment, not to mention the least vulnerable to generic competition.  In this article, I will analyze the implications of the transaction and what it could mean for Biogen’s future.

Biogen Idec Inc (NASDAQ:BIIB)The Deal

Biogen announced that it has agreed to purchase Elan’s interest in Tysabri (natalizumab) to gain all the rights to Tysabri. On the closing of this transaction, the previous collaboration agreement in which worldwide Tysabri’s profits were split 50/50 will be terminated.

Biogen Idec will use its existing cash to make a payment of $3.25 billion to Elan and make future contingent payments amounting to 12% of global net sales of Tysabri for the first twelve months, and thereafter, on a tiered basis.

Biogen Idec anticipates the transaction will add $0.20 to $0.30 to 2013 GAAP earnings per share and $0.50 to $0.60 to non-GAAP earnings per share in 2013 and continue to be accretive in the future, depending on the sales.  The agreement gives Biogen full control of the multiple sclerosis drug and ends a long partnership that has sometimes been contentious.

The Rationale Behind The Deal

Analysts have long speculated that Biogen could acquire Elan to take control of Tysabri, but the deal gives Biogen what it wants without the burden of any excess baggage. The timing intrigues some investors because the company is poised to launch a new MS drug, BG-12, in the first quarter, which will be sold under the brand name Tecfidera.

Tysabri is widely expected to become the preferred treatment for multiple sclerosis but will lose patent protection in the mid to late 2020’s. The rationale could be that oral drugs such as BG-12 (small molecule drugs) are easier to replicate by genetics manufacturers rather than complex, large molecule biologic drugs such as Tysabri that are given by infusion. Tysabri is far more effective than BG-12 and therefore unlikely to be effected by small molecule treatments.  Biogen is also likely to continue to benefit after losing patent protection on BG-12.


Tysabri is generally considered to be the most effective treatment for multiple sclerosis, but it has been connected with a potentially deadly brain infection known as progressive multifocal leukoencephalopathy, or PML. It is currently approved to treat patients who do not respond to alternative therapies or cannot tolerate them. Biogen has now developed a test that can predict with a high degree of accuracy which patients are likely to develop PML, thereby eliminating the anxiety among physicians and patients that has held back the growth of the drug.

Last month the company applied to U.S. and European regulators for the marketing rights for the drug for newly diagnosed patients who have tested negative for antibodies to the JC virus, the cause of PML.  Around 40% of MS patients are JCV negative. Total sales of Tysabri in 2012 rose 8% to $1.6 billion and analysts predict sales of the drug in 2013 to be $1.86 billion and grow to $2.34 billion in 2015.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!